Swiss drugmaker Roche Holding AG (ROG.S) said on Thursday it would buy the rest of U.S. cancer data company Flatiron Health for $1.9 billion to speed development of cancer medicines and support its efforts to price them based on how well they work.
Startup Maryland today unveiled the Overall Great Eight and other sub-category finalist for the Pitch Across Maryland Competitions. Startup Maryland is proud to showcase the finalists along with all the ventures who participated in the 2017 STRT1UP Roadshow celebration of innovation and entrepreneurship. This year’s Overall Great Eight Finalist are listed below with a link to their pitch video.
Looking for a deal in your backyard? The NIH is the world’s largest investor in early stage life sciences companies. Over 1000 companies annually tap into NIH’s SBIR and STTR program for nondilutive funding to the tune of $980M in FY17. Did you know the NIH maintains RePORTER, an online database, of all funded companies and projects?
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has closed the acquisition of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, including its commercial and development assets.
The National Institutes of Health has been funding fewer clinical trials in recent years, according to new Johns Hopkins University research.
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today the pricing of its previously announced underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $8.00 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Pieris, are expected to be $44.0 million. In addition, Pieris has granted the underwriters a 30-day option to purchase up to 825,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about February 16, 2018, subject to customary closing conditions.
Host: UM BioPark & Wexford Science + Technology
Location: UM BioPark The Nook Cafe 801 W. Baltimore Street Baltimore Maryland 21201
Time: Thursday, February 22, 2018 5:00pm to 6:30pm
Mingle with BioPark tenants, our UM Ventures staff, UMB faculty and leaders in Baltimore’s technology community.
MaxCyte, the global cell-based medicines and technology company, announces that 30-year life sciences industry veteran Richard Douglas, Ph.D., has been appointed to the Company’s Board of Directors as an Independent Non-Executive Director.
Is wood the next advanced material?
Scientists at the University of Maryland reported last week that they’ve discovered a way to treat wood to make it 12 times stronger than natural wood and 10 times tougher. According to Liangbing Hu, one the lead researchers in the paper published in Nature, their wood is so strong and durable that it can compete with steel, titanium alloys, and even carbon fiber–but at an infinitely much lower price point.
Brown Advisory—an investment and strategic advisory firm committed to making a material and positive difference in the lives of its clients—is excited to join forces with network-driven venture capital firm, NextGen Venture Partners (“NextGen”). On Feb. 22, 2018, the NextGen team will officially join their new Brown Advisory colleagues in offices across the United States.